

Cancer Treatment Pathways

Provider Tip Sheet

Table of Contents

Table of Contents.....	1
Legend.....	2
Tumor Type (On Pathway).....	2
Bladder Cancer.....	2
Breast Cancer.....	2
Biliary Tract Cancer	6
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).....	6
Chronic Myelogenous Leukemia (CML).....	7
Colorectal Cancer.....	8
Gastric, Esophageal, and Gastroesophageal Junction Adenocarcinoma	9
Head and Neck Cancer.....	10
Hepatocellular Carcinoma	10
Hodgkins Lymphoma.....	11
Kidney Cancer (Clear Cell Carcinoma).....	11
Non-Small Cell Lung Cancer (NSCLC)	12
Small Cell Lung Cancer (SCLC).....	14
Cutaneous Melanoma.....	14
Multiple Myeloma	15
NHL: Diffuse Large B-Cell Lymphoma.....	16
NHL: Follicular Lymphoma (grades 1-3b).....	17
Marginal Zone Lymphoma (Gastric MALT, Splenic Marginal Zone).....	17
Mantle Cell Lymphoma.....	17
Ovarian Cancer (Epithelial).....	18
Pancreatic Adenocarcinoma	19
Prostate Cancer	19
Testicular Cancer (Germ Cell Tumors).....	21
Uterine Cancer (Epithelial Cancer).....	21

Legend

Topic	Definition
Pathway Required Biomarkers	Biomarker names within the system
Alternative name(s) for Pathway Required Biomarkers	Alternative names for biomarkers (not listed within the system)
Key Clinical Indicators	Standout clinical requirements for pathway treatments
Tumor type (On Pathway)	This tip sheet includes only Carelon pathway-eligible regimens by tumor type, outlining required biomarkers, clinical indicators, and injectable/oral combinations where oral therapy must be included in the prior authorization request to receive pathway credit. It does not reflect all regimens covered under medical policy.

Tumor Type (On Pathway)

Bladder Cancer

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
ddMVAC*: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with G-CSF	None	N/A	With G-CSF
BCG: bacillus calmette-guerin, intravesical	None	N/A	After TURBT or resection
Gemcitabine (Gemzar), intravesical	None	N/A	low grade histology
Enfortumab vedotin plus pembrolizumab	None	N/A	

Breast Cancer

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
TCH+P: docetaxel (Taxotere), carboplatin, trastuzumab, and pertuzumab (Perjeta)	HER2	HER2 expression or amplification	
ddAC → weekly T: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	

Breast Cancer (cont.)

Weekly T → ddAC: weekly paclitaxel followed by dose dense doxorubicin (Adriamycin) and cyclophosphamide	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
TC: docetaxel (Taxotere) and cyclophosphamide	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Pembrolizumab (Keytruda), carboplatin, and paclitaxel	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Pembrolizumab (Keytruda), doxorubicin, and cyclophosphamide	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
TH: paclitaxel and trastuzumab	HER2	HER2 expression or amplification	
Ado-trastuzumab emtansine (Kadcyla)	HER2	HER2 expression or amplification	Residual Disease following Neoadjuvant Therapy
Pembrolizumab (Keytruda), following neoadjuvant pembrolizumab-based treatment	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Capecitabine (Xeloda)	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	Adjuvant Therapy Only: Residual Disease following Neoadjuvant Therapy
Pertuzumab (Perjeta), trastuzumab, and docetaxel (Taxotere)	HER2	HER2 expression or amplification	
Pertuzumab (Perjeta), trastuzumab, and paclitaxel	HER2	HER2 expression or amplification	
Fam-trastuzumab deruxtecan-nxki (Enhertu)	HER2	HER2 expression or amplification	

Breast Cancer (cont.)

Pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane)	HER2, ER/PR CPS (PD-L1)	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda) and paclitaxel	HER2, ER/PR, CPS (PD-L1)	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda), gemcitabine (Gemzar), and carboplatin	HER2, ER/PR, CPS (PD-L1)	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status PD-L1, Combined Positive Score (CPS)	
Doxorubicin (Adriamycin)	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Gemcitabine (Gemzar)	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Paclitaxel	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Vinorelbine (Navelbine)	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	

Breast Cancer (cont.)

Sacituzumab govitecan-hziy (Trodelyv)	HER2, ER/PR	HER2 expression or amplification Progesterone Receptor Status Estrogen Receptor Status	
Anastrozole (Arimidex) and ribociclib (Kisqali)	HER2	HER2 expression or amplification	
Letrozole (Femara) and ribociclib (Kisqali)	HER2	HER2 expression or amplification	
Anastrozole (Arimidex)	HER2	HER2 expression or amplification	
Fulvestrant (Faslodex) high dose	HER2	HER2 expression or amplification	
Fulvestrant (Faslodex) and ribociclib (Kisqali) *Must include oral and injectable drugs to be on pathway*	HER2	HER2 expression or amplification	
Letrozole (Femara)	HER2	HER2 expression or amplification	
Tamoxifen	HER2	HER2 expression or amplification	
Exemestane (Aromasin)	HER2	HER2 expression or amplification	
Fulvestrant (Faslodex) and alpelisib (PIQRAY) *Must include oral and injectable drugs to be on pathway*	PIK3CA/AKT1/ PTEN HER2	PIK3CA mutation PTEN HER2 expression or amplification	Prior CDK4/6 inhibitor therapy Prior therapy for PK3CA, AKT1 or PTEN
Fulvestrant (Faslodex) and capivasertib (TRUQAP) *Must include oral and injectable drugs to be on pathway*	PIK3CA/AKT1/ PTEN HER2	PIK3CA mutation PTEN HER2 expression or amplification	Prior CDK4/6 inhibitor therapy Prior therapy for PK3CA, AKT1 or PTEN

Biliary Tract Cancer

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Durvalumab (Imfinzi), gemcitabine (Gemzar), and cisplatin	None	N/A	
Pembrolizumab (Keytruda), gemcitabine (Gemzar), and cisplatin	None	N/A	

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Acalabrutinib (Calquence)	17p Deletion TP53 status	TP53 mutation 17p13 deletion	
Ibrutinib (Imbruvica)	17p Deletion TP53 status	TP53 mutation 17p13 deletion	
Zanubrutinib (Brukinsa)	17p Deletion TP53 status	TP53 mutation 17p13 deletion	
Venetoclax (Venclexta) and obinutuzumab (Gazyva) *Must include oral and injectable drugs to be on pathway*	17p Deletion TP53 Mutation	TP53 mutation 17p13 deletion	
Venetoclax (Venclexta) and rituximab *Must include oral and injectable drugs to be on pathway*	17p Deletion TP53 status	TP53 mutation 17p13 deletion	

Chronic Myelogenous Leukemia (CML)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Imatinib (Gleevec)	None	N/A	Low, Intermediate, or High-Risk Disease
Dasatinib (Sprycel)	None	N/A	New Diagnosis: Intermediate or High-Risk Disease Second Line of Therapy (2nd Line): Resistant disease to primary treatment, Suboptimal Response, or Intolerance to 1 st Line
Nilotinib (Tasigna)	None	N/A	New Diagnosis: Intermediate or High-Risk Disease Second Line of Therapy (2nd Line): Resistant disease to primary treatment, Suboptimal Response, or Intolerance to 1 st Line
Bosutinib (Bosulif)	None	N/A	Resistant disease to primary treatment, Suboptimal Response, or Intolerance to 1st Line
Ponatinib (Iclusig)	T315I mutation	T315I mutation	

Colorectal Cancer

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Capecitabine (Xeloda)	None	N/A	
FULV: fluorouracil (5FU) and leucovorin	None	N/A	
CAPOX: capecitabine (Xeloda) and oxaliplatin (limited to 3 months duration) *Must include oral and injectable drugs to be on pathway*	None	N/A	
FOLFOX: fluorouracil (5-FU), leucovorin, and oxaliplatin	KRAS NRAS	KRAS NRAS	
FOLFIRI: fluorouracil (5FU), leucovorin, and irinotecan (Camptosar)	KRAS NRAS	KRAS NRAS	
FOLFIRINOX: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin	KRAS NRAS	KRAS NRAS	
FOLFIRI + panitumumab: fluorouracil (5FU), leucovorin, and irinotecan (Camptosar) with panitumumab (Vectibix)	KRAS NRAS BRAF	KRAS NRAS BRAF	
FOLFOX + panitumumab: fluorouracil (5-FU), leucovorin, and oxaliplatin with panitumumab (Vectibix)	KRAS NRAS BRAF	KRAS NRAS BRAF	
Irinotecan (Camptosar) and panitumumab (Vectibix)	KRAS NRAS BRAF	KRAS NRAS BRAF	
FOLFOX + atezolizumab: fluorouracil (5FU), leucovorin, oxaliplatin, and atezolizumab (Tecentriq)	MSI/MMR	Microsatellite Instability/mismatch repair	
Pembrolizumab (Keytruda)	MSI/MMR	Microsatellite Instability/mismatch repair	
FOLFOX + Encorafenib + Cetuximab: fluorouracil (5FU), leucovorin, oxaliplatin, encorafenib (Braftovi), and cetuximab (Erbix) *Must include oral and injectable drugs to be on pathway*	BRAF V600E	BRAF V600E mutation	

Gastric, Esophageal, and Gastroesophageal Junction Adenocarcinoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
FLOT: Fluorouracil (5FU), leucovorin, oxaliplatin, and docetaxel (Taxotere)	None	N/A	
Paclitaxel and carboplatin with concurrent RT	None	N/A	
Fluorouracil (5FU) and leucovorin with concurrent RT	None	N/A	
Nivolumab (Opdivo)	None	N/A	
Cisplatin, fluorouracil (5FU), and trastuzumab	HER2	HER2 expression or amplification	
Fluorouracil (5FU) and Cisplatin	HER2	HER2 expression or amplification	
FLO/FOLFOX: fluorouracil (5FU), leucovorin, and oxaliplatin	HER2	HER2 expression or amplification	
FLP: fluorouracil (5FU), leucovorin, and cisplatin	HER2	HER2 expression or amplification	
FOLFOX + nivolumab: fluorouracil (5FU), leucovorin, oxaliplatin, and nivolumab (Opdivo)	HER2 CPS (PD-L1)	HER2 expression or amplification PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda), fluorouracil (5FU) and cisplatin	HER2 CPS (PD-L1)	HER2 expression or amplification PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda), capecitabine (Xeloda) and oxaliplatin *Must include oral and injectable drugs to be on pathway*	HER2 CPS (PD-L1)	HER2 expression or amplification PD-L1, Combined Positive Score (CPS)	
Irinotecan (Camptosar)	None	N/A	
Paclitaxel	None	N/A	
Trastuzumab deruxtecan (Enhertu)	HER2	HER2 expression or amplification	

Head and Neck Cancer

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
High dose cisplatin* with concurrent RT	None	N/A	
Carboplatin, fluorouracil (5FU), and cetuximab (Erbix)	None	N/A	
Cisplatin, fluorouracil (5FU), and cetuximab (Erbix)	None	N/A	
Pembrolizumab (Keytruda)	CPS (PD-L1)	PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda), carboplatin, and fluorouracil (5FU)	CPS (PD-L1)	PD-L1, Combined Positive Score (CPS)	
Pembrolizumab (Keytruda), cisplatin, and fluorouracil (5FU)	CPS (PD-L1)	PD-L1, Combined Positive Score (CPS)	
Cisplatin with concurrent RT	None	N/A	
Cisplatin and gemcitabine (Gemzar) followed by concurrent cisplatin/RT	None	N/A	
Cisplatin, gemcitabine (Gemzar), and toripalimab (Loptorzi)	None	N/A	
Nivolumab (Opdivo)	CPS (PD-L1)	PD-L1, Combined Positive Score (CPS)	
Paclitaxel	None	N/A	

Hepatocellular Carcinoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Atezolizumab (Tecentriq) and bevacizumab	None	N/A	
Regorafenib (Stivarga)	None	N/A	
Cabozantinib (Cabometyx)	None	N/A	

Hodgkins Lymphoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT	None	N/A	
A-AVD: brentuximab vedotin (Adcetris), doxorubicin (Adriamycin), vinblastine, and dacarbazine	None	N/A	
Nivolumab-AVD: nivolumab (Opdivo), doxorubicin (Adriamycin), vinblastine, and dacarbazine	None	N/A	

Kidney Cancer (Clear Cell Carcinoma)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Nivolumab (Opdivo) and cabozantinib (Cabometyx) *Must include oral and injectable drugs to be on pathway*	None	N/A	
Nivolumab (Opdivo) and ipilimumab (Yervoy)	None	N/A	Unfavorable Risk
Pembrolizumab (Keytruda) and axitinib (Inlyta) *Must include oral and injectable drugs to be on pathway*	None	N/A	

Non-Small Cell Lung Cancer (NSCLC)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Cisplatin and etoposide	None	N/A	
Paclitaxel and carboplatin	None	N/A	Frist Line of Therapy (1st Line) Stage IIIB-IV, and Recurrent Only: Ineligible for Immunotherapy
Cisplatin and gemcitabine (Gemzar)	None	N/A	Frist Line of Therapy (1st Line) Stage IIIB-IV, and Recurrent Only: Ineligible for Immunotherapy
Cisplatin and pemetrexed (Alimta)	None	N/A	First Line of Therapy (1st Line) Stage IIIB-IV, and Recurrent Only: Ineligible for Immunotherapy
Cisplatin and vinorelbine (Navelbine)	None	N/A	
Cemiplimab-rwlc (Libtayo)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations-EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Pembrolizumab (Keytruda)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations-EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Cisplatin and paclitaxel	None	N/A	Ineligible for Immunotherapy
Carboplatin and gemcitabine (Gemzar)	None	N/A	Ineligible for Immunotherapy
Alectinib (Alecensa)	ALK	ALK gene rearrangement	
Lorlatinib (Lobrena)	ALK	ALK gene rearrangement	

Non-Small Cell Lung Cancer (NSCLC) (cont.)

Osimertinib (Tagrisso)	EGFR exon19 deln EGFR ex21 L858R	EGFR exon 19 deletion EGFR exon 21 L858R mutation	
Carboplatin pemetrexed, and osimertinib (Tagrisso) *Must include oral and injectable drugs to be on pathway*	EGFR exon19 deln EGFR ex21 L858R	EGFR exon 19 deletion EGFR exon 21 L858R mutation	
Cisplatin, pemetrexed, and osimertinib (Tagrisso) *Must include oral and injectable drugs to be on pathway*	EGFR exon19 deln EGFR ex21 L858R	EGFR exon 19 deletion EGFR exon 21 L858R mutation	
Carboplatin pemetrexed (Alimta), and pembrolizumab (Keytruda)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations- EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Cisplatin, pemetrexed (Alimta), and pembrolizumab (Keytruda)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations- EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Carboplatin pemetrexed (Alimta), and cemiplimab-rwlc (Libtayo)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations- EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Cisplatin, pemetrexed (Alimta), and cemiplimab-rwlc (Libtayo)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations- EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Atezolizumab (Tecentriq)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations- EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Carboplatin, paclitaxel, and bevacizumab	None	N/A	Ineligible for Immunotherapy

Non-Small Cell Lung Cancer (NSCLC) (cont.)

Carboplatin and pemetrexed (Alimta)	None	N/A	Ineligible for Immunotherapy
Pembrolizumab (Keytruda), carboplatin, and paclitaxel	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations-EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Carboplatin, paclitaxel, and cemiplimab-rwlc (Libtayo)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations-EGFR exon 19 del/21 L858R, ALK rearr, ROS1	
Cisplatin, paclitaxel, and cemiplimab-rwlc (Libtayo)	CPS (PD-L1) Actionable mutn	PD-L1, Combined Positive Score (CPS) Actionable mutations-EGFR exon 19 del/21 L858R, ALK rearr, ROS1	

Small Cell Lung Cancer (SCLC)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Carboplatin and etoposide	None	N/A	
Cisplatin and etoposide	None	N/A	
Atezolizumab (Tecentriq), carboplatin, and etoposide	None	N/A	

Cutaneous Melanoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Pembrolizumab (Keytruda)	None	N/A	
Nivolumab (Opdivo) and ipilimumab (Yervoy)	None	N/A	

Cutaneous Melanoma (cont.)

Nivolumab (Opdivo)	None	N/A	
Encorafenib (Braftovi) and binimetinib (Mektovi)	BRAF	BRAF	Ineligible for Immunotherapy

Multiple Myeloma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
VRD/VDR: bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Transplant Candidates
D-VRd: daratumumab (Darzalex), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Transplant Candidates
CyBorD or VDC: bortezomib (Velcade), cyclophosphamide, and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Non-Transplant Candidates
DRd: daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Frist Line of Therapy (1st Line) Only: Non-Transplant Candidates
Rd: lenalidomide (Revlimid) and low-dose dexamethasone	None	N/A	Non-Transplant Candidates
Isatuximab-VRd: bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone with isatuximab (Sarclisa) *Must include oral and injectable drugs to be on pathway*	None	N/A	Non-Transplant Candidates
Vd: bortezomib (Velcade) and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Non-Transplant Candidates

Multiple Myeloma (cont.)

CRd or KRd: carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	
DVd: daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	
PVd: pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone *Must include oral and injectable drugs to be on pathway*	None	N/A	Prior lenalidomide and Proteasome inhibitor therapy
Lenalidomide (Revlimid)	Post-transplant? High risk disease?	Is the individual post-transplant? Does the individual have high risk disease?	Standard Risk (is on pathway)

NHL: Diffuse Large B-Cell Lymphoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
R-CHOP (21): cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab *Must include oral and injectable drugs to be on pathway*	None	N/A	
R-CEOP: Cyclophosphamide, etoposide, vincristine (Vincasar), prednisone, and rituximab *Must include oral and injectable drugs to be on pathway*	Anthracycline CI	Anthracycline contraindicated	

NHL: Follicular Lymphoma (grades 1-3b) Marginal Zone Lymphoma (Gastric MALT, Splenic Marginal Zone)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Clarithromycin and amoxicillin	None	N/A	H. pylori positive (Gastric Malt Only)
Clarithromycin and metronidazole	None	N/A	H. pylori positive (Gastric Malt Only)
Rituximab	None	N/A	
BR: Bendamustine (Bendeka, Treanda) and rituximab	None	N/A	
R-CHOP (21): cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab *Must include oral and injectable drugs to be on pathway*	None	N/A	
R-CVP: Cyclophosphamide, vincristine (Vincasar), prednisone, and rituximab *Must include oral and injectable drugs to be on pathway*	None	N/A	
R-CEOP: Cyclophosphamide, etoposide, vincristine (Vincasar), prednisone, and rituximab *Must include oral and injectable drugs to be on pathway*	None	N/A	

Mantle Cell Lymphoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Alternating R-CHOP/R-DHAP: cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, rituximab alternating with dexamethasone, cisplatin, cytarabine (Ara-C), and rituximab *Must include oral and injectable drugs to be on pathway*	None	N/A	Candidates for Autologous Stem Cell Transplant (ASCT)

Mantle Cell Lymphoma (cont.)

Nordic Regimen: dose intense rituximab, cyclophosphamide, vincristine (Vincasar), doxorubicin (Adriamycin), prednisone alternating with rituximab and high dose cytarabine (AraC) *Must include oral and injectable drugs to be on pathway*	None	N/A	Candidates for Autologous Stem Cell Transplant (ASCT)
BR: bendamustine (Bendeka, Treanda) and rituximab	None	N/A	Frist Line of Therapy (Stage IV) Only: Non-Candidates for Autologous Stem Cell Transplant (ASCT)
Acalabrutinib (Calquence)	None	N/A	
Bortezomib (Velcade)	None	N/A	
Lenalidomide (Revlimid)	None	N/A	

Ovarian Cancer (Epithelial)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Carboplatin and paclitaxel	None	N/A	Initial treatment for Metastatic or Recurrent Disease Only: Platinum sensitive
Carboplatin	None	N/A	Initial treatment for Metastatic or Recurrent Disease Only: Platinum sensitive
Carboplatin and gemcitabine (Gemzar)	None	N/A	Initial treatment for Metastatic or Recurrent Disease Only: Platinum sensitive
Bevacizumab	None	N/A	Platinum resistant
Docetaxel (Taxotere)	None	N/A	Platinum resistant
Gemcitabine (Gemzar)	None	N/A	Platinum resistant

Ovarian Cancer (Epithelial) (cont.)

Paclitaxel	None	N/A	Platinum resistant
Liposomal doxorubicin (Doxil)	None	N/A	Platinum resistant
Paclitaxel and bevacizumab	None	N/A	Platinum resistant
Niraparib (Zejula)	None	N/A	Platinum sensitive
Olaparib (Lynparza)	None	N/A	Platinum sensitive
Rucaparib (Rubraca)	None	N/A	Platinum sensitive

Pancreatic Adenocarcinoma

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
FOLFIRINOX: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin	None	N/A	
Capecitabine (Xeloda) and gemcitabine (Gemzar) *Must include oral and injectable drugs to be on pathway*	None	N/A	
FULV: fluorouracil (5FU) and leucovorin	None	N/A	
Gemcitabine (Gemzar)	None	N/A	
Gemcitabine (Gemzar) and albumin-bound-paclitaxel (Abraxane)	None	N/A	

Prostate Cancer

Regimen *Must include oral and injectable drugs to be on pathway*	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Goserelin (Zoladex)	None	N/A	
Leuprolide (Eligard/Lupron)	None	N/A	
Triptorelin (Trelstar)	None	N/A	
Goserelin (Zoladex) with abiraterone (Zytiga)	None	N/A	
Leuprolide (Eligard/Lupron) with abiraterone (Zytiga)	None	N/A	

Prostate Cancer (cont.)

Triptorelin (Trelstar) with abiraterone (Zytiga)	None	N/A	
Abiraterone (Zytiga), docetaxel (Taxotere), and prednisone with triptorelin (Trelstar)	None	N/A	Castration Sensitive Disease
Abiraterone (Zytiga), docetaxel (Taxotere), and prednisone with goserelin (Zoladex)	None	N/A	Castration Sensitive Disease
Abiraterone (Zytiga), docetaxel (Taxotere), and prednisone with leuprolide (Eligard/Lupron)	None	N/A	Castration Sensitive Disease
Apalutamide (Erleada) with leuprolide (Eligard/Lupron)	None	N/A	Castration Sensitive Disease
Apalutamide (Erleada) with goserelin (Zoladex)	None	N/A	Castration Sensitive Disease
Apalutamide (Erleada) with triptorelin (Trelstar)	None	N/A	Castration Sensitive Disease
Darolutamide (Nubeqa) and docetaxel (Taxotere) with leuprolide (Eligard/Lupron)	None	N/A	Castration Sensitive Disease
Darolutamide (Nubeqa) and docetaxel (Taxotere) with goserelin (Zoladex)	None	N/A	Castration Sensitive Disease
Darolutamide (Nubeqa) and docetaxel (Taxotere) with triptorelin (Trelstar)	None	N/A	Castration Sensitive Disease
Enzalutamide (Xtandi) with goserelin (Zoladex)	None	N/A	
Enzalutamide (Xtandi) with leuprolide (Eligard/Lupron)	None	N/A	
Enzalutamide (Xtandi) with triptorelin (Trelstar)	None	N/A	
Abiraterone (Zytiga) and prednisone with goserelin (Zoladex)	None	N/A	
Abiraterone (Zytiga) and prednisone with leuprolide (Eligard/Lupron)	None	N/A	
Abiraterone (Zytiga) and prednisone with triptorelin (Trelstar)	None	N/A	
Docetaxel (Taxotere) with goserelin (Zoladex)	None	N/A	Castration Resistant Disease
Docetaxel (Taxotere) with leuprolide (Eligard/Lupron)	None	N/A	Castration Resistant Disease
Docetaxel (Taxotere) with triptorelin (Trelstar)	None	N/A	Castration Resistant Disease

Testicular Cancer (Germ Cell Tumors)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
BEP: bleomycin, etoposide, and cisplatin	None	N/A	Stages:II-III A and IS Seminoma and Non-Seminoma Stages IIIB and IIIC Seminoma with Good and Intermediate Risk OR Non-Seminoma
EP: etoposide and cisplatin	None	N/A	Stages:II-III A and IS Seminoma and Non-Seminoma Stages IIIB and IIIC Seminoma with Good Risk

Uterine Cancer (Epithelial Cancer)

Regimen	Pathway Required Biomarkers	Alternative name(s) for Pathway Required Biomarkers	Key Clinical Indicators
Carboplatin and paclitaxel	None	N/A	
Carboplatin, paclitaxel, and dostarlimab-gxly (Jemperli)	None	N/A	
Carboplatin, paclitaxel, and pembrolizumab	None	N/A	